Julen Rodríguez Castejón-rekin lankidetzan egindako argitalpenak (21)

2024

  1. Gene therapy with lipid nanoparticles for Fabry disease: Leveraging E-selectin for targeted delivery to endothelial cells

    Journal of Drug Delivery Science and Technology, Vol. 99

  2. Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems

    BioDrugs, Vol. 38, Núm. 5, pp. 657-680

  3. Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review

    Drug Delivery and Translational Research, Vol. 14, Núm. 10, pp. 2615-2628

2023

  1. Expression of a conserved sequence of SARS-CoV-2 for panβ-coronavirus vaccine development

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  2. Modelo SoTL para evaluar el aprendizaje basado en la investigación en el desarrollo de TFG sobre atención farmacéutica

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  3. Nanopartículas lipídicas funcionalizadas con GalNAc para suplementación génica: aplicación en la enfermedad de Fabry

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  4. Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease

    Pharmaceutics, Vol. 15, Núm. 7

  5. siRNA vectors based on golden lipid nanoparticles for Fabry Disease

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

2022

  1. Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease

    Nanomaterials, Vol. 12, Núm. 14

  2. mRNA delivery technologies: Toward clinical translation

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 207-293

2021

  1. Functionalised SLNs-based nanovectors for gene therapy in Fabry disease: The liver as an α-Galactosidase A factory

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 46-48

  2. Mrna-based nanomedicinal products to address corneal inflammation by interleukin-10 supplementation

    Pharmaceutics, Vol. 13, Núm. 9

  3. Substrate reduction therapy based on siRNA for Fabry Disease

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 84-86

  4. α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice

    Pharmaceutics, Vol. 13, Núm. 6

2020

  1. Gene Therapy

    Advances in Biochemical Engineering/Biotechnology (Springer), pp. 321-368

  2. Nanomedicines to deliver mRNA: State of the art and future perspectives

    Nanomaterials, Vol. 10, Núm. 2

  3. Nucleic Acid Delivery by Solid Lipid Nanoparticles Containing Switchable Lipids: Plasmid DNA vs. Messenger RNA

    Molecules (Basel, Switzerland), Vol. 25, Núm. 24

  4. Nuevo servicio de seguridad y uso de medicamentos sujetos a seguimiento adicional (SSUM) en farmacia comunitaria: resultados iniciales = Jarraipen gehigarria behar duten sendagaien segurtasuna eta erabilera ebaluatzeko zerbitzu berria (SSUM) farmazia komunitarioan: hasierako emaitzak

    Congreso Nacional de Farmacéuticos Comunitarios (9º. 2020). Reunión Internacional de Farmacéuticos Comunitarios (2º. 2020)

  5. Nuevo servicio de seguridad y uso de medicamentos sujetos a seguimiento adicional (ssum) en farmacia comunitaria: resultados iniciales

    Congreso Nacional de Farmacéuticos Comunitarios (9º. Bilbao. 2020)

  6. Topical administration of sln-based gene therapy for the treatment of corneal inflammation by de novo il-10 production

    Pharmaceutics, Vol. 12, Núm. 6, pp. 1-23